Related Experiment Videos
Predictive testing for Huntington's disease: a universal model?
1Centre for Molecular Medicine & Therapeutics, University of British Columbia, 950 West 28th Avenue, V5Z 4H4, Vancouver, BC, Canada. mrh@cmmt.ubc.ca <mrh@cmmt.ubc.ca>
The Lancet. Neurology
|July 10, 2003
Summary
No abstract available in PubMed .
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease.
Journal of Huntington's disease·2026
Same author
Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation.
International journal of molecular sciences·2026
Same author
Treatment of Huntington's disease with a pan-HTT-targeting CRISPR nuclease.
Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author
Silencing of human <i>HTT</i> by targeted CRISPR/dCas9-mediated epigenetic editing.
Journal of Huntington's disease·2026
Same author
Treatment of Huntington's disease with a pan-HTT-targeting CRISPR nuclease.
bioRxiv : the preprint server for biology·2026
Same author
Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases.
Pharmaceuticals (Basel, Switzerland)·2025
Same journal
Resolution of expression of concern-Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
The Lancet. Neurology·2026
Same journal
UCL Queen Square Institute of Neurology: 75 years of innovation.
The Lancet. Neurology·2026
Same journal
Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.
The Lancet. Neurology·2026